Healthcor Management Lowers stake in Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) : Healthcor Management reduced its stake in Neurocrine Biosciences by 37.93% during the most recent quarter end. The investment management company now holds a total of 450,000 shares of Neurocrine Biosciences which is valued at $21,771,000 after selling 275,000 shares in Neurocrine Biosciences , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Neurocrine Biosciences makes up approximately 1.15% of Healthcor Management’s portfolio.

Other Hedge Funds, Including , Nexthera Capital Lp boosted its stake in NBIX in the latest quarter, The investment management firm added 15,000 additional shares and now holds a total of 42,000 shares of Neurocrine Biosciences which is valued at $2,031,960. Neurocrine Biosciences makes up approx 1.99% of Nexthera Capital Lp’s portfolio.Janus Capital Management reduced its stake in NBIX by selling 65,012 shares or 2.91% in the most recent quarter. The Hedge Fund company now holds 2,166,573 shares of NBIX which is valued at $104,818,802. Neurocrine Biosciences makes up approx 0.09% of Janus Capital Management’s portfolio. Bluemountain Capital Management added NBIX to its portfolio by purchasing 5,901 company shares during the most recent quarter which is valued at $285,490. Neurocrine Biosciences makes up approx 0.01% of Bluemountain Capital Management’s portfolio.First Trust Advisors Lp reduced its stake in NBIX by selling 21,250 shares or 3.33% in the most recent quarter. The Hedge Fund company now holds 617,037 shares of NBIX which is valued at $30,833,339. Neurocrine Biosciences makes up approx 0.09% of First Trust Advisors Lp’s portfolio.

Neurocrine Biosciences opened for trading at $50.66 and hit $51.05 on the upside on Wednesday, eventually ending the session at $50.9, with a gain of 0.12% or 0.06 points. The heightened volatility saw the trading volume jump to 844,457 shares. Company has a market cap of $4,416 M.

On the company’s financial health, Neurocrine Biosciences reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.49.During the same quarter in the previous year, the company posted $-0.28 EPS.

Many Wall Street Analysts have commented on Neurocrine Biosciences. H.C. Wainwright Initiated Neurocrine Biosciences on Jun 29, 2016 to “Buy”, Price Target of the shares are set at $80.

Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.

Leave a Reply

Neurocrine Biosciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Neurocrine Biosciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.